Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Radiation Dosimetry and Preliminary Efficacy of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer

NCT06139575 is registered in ClinicalTrials.gov with Bivision Pharmaceuticals, Inc. as lead sponsor.

NCT NCT06139575
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06139575 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Radiation Dosimetry and Preliminary Efficacy of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer
Lead sponsor
Bivision Pharmaceuticals, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 22, 2023
Completion date
July 31, 2027
Enrollment
90 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer